As the landscape of cancer treatment evolves with T-cell engager therapies branching out from hematologic malignancies to solid tumors, the importance of nurses and advanced practice providers (APPs) in navigating the spectrum of immune-related toxicities cannot be overstated. At the 2025 Immune Cell Effector Therapies (ICE-T) Conference, experts shed light on the risks associated with T-cell engagers such as ICANS, CRS, and HLH, emphasizing the pivotal role of healthcare professionals in ensuring patient safety and well-being in the face of these novel challenges.
Dr. Daniel Carrizosa, a seasoned oncologist at Atrium Health Levine Cancer Institute, underscored the unique adverse effects encountered with bispecific T-cell engagers like tarlatamab (Imdelltra) in solid tumors, including ICANS and CRS, which are less common in this setting compared to hematologic cancers. This shift necessitates a proactive approach to monitoring and managing these toxicities, where the vigilance and expertise of nurses and APPs are indispensable in early detection and intervention to optimize patient outcomes.
Dr. Nausheen Ahmed, an expert in hematologic malignancies, drew attention to the significance of maintaining normalcy for patients undergoing immune effector cell therapies, emphasizing simple yet crucial measures such as preserving circadian rhythms and addressing sensory impairments to mitigate neurological toxicities. By creating a conducive environment that supports patients’ well-being and mental clarity, healthcare providers can potentially prevent or alleviate treatment-related complications, particularly in vulnerable populations like older patients receiving intensive therapies.
Dr. Al-Ola Abdallah highlighted the evolving landscape of CAR T-cell therapy in hematologic malignancies, pointing out emerging adverse events such as HLH and prolonged cytopenias that demand heightened awareness and proactive management strategies from healthcare teams. The increasing utilization of CAR T-cell and bispecific T-cell engagers necessitates a deep understanding of both short-term and long-term toxicities among nurses and APPs to facilitate early recognition, intervention, and holistic care for patients grappling with these complex treatment challenges.
In the realm of T-cell engager therapy, the roles of nurses and APPs extend beyond traditional patient care to encompass critical functions as liaisons in recognizing and responding to key toxicities like CRS, neurotoxicity, and infections. By serving as frontline advocates for patient safety and well-being, these healthcare professionals play a pivotal role in enhancing treatment outcomes, improving patient experiences, and advancing the field of oncology care in the era of evolving immunotherapies.
Key Takeaways:
– Nurses and APPs are instrumental in proactively managing immune-related toxicities associated with T-cell engager therapies in solid tumors, requiring a multidisciplinary approach for optimal patient care.
– Maintaining normalcy for patients undergoing immune effector cell therapies is essential to mitigate treatment-related complications, emphasizing the importance of holistic supportive care measures.
– The expanding landscape of CAR T-cell therapy underscores the critical need for healthcare providers to stay abreast of emerging adverse events and complications, necessitating early detection and intervention for improved patient outcomes.
– Nurses and APPs serve as vital liaisons in recognizing and addressing key toxicities in T-cell engager therapy, playing a crucial role in safeguarding patient well-being and optimizing treatment efficacy.
Tags: cell therapies, clinical trials
Read more on oncnursingnews.com